HOME >> BIOLOGY >> NEWS
Mayo Clinic researchers enhance safety and effectiveness of therapeutic virus that fights cancer

Rochester, Minn. -- Mayo Clinic researchers working with colleagues in Germany have devised a much-needed multilevel safety feature for viruses used to treat cancer. In the process of making cancer-killing viruses more specific to cancer tumor cells, they report having improved the therapeutic effectiveness of viruses. They did this by engineering a modified measles virus that turns on only in the presence of secretions specific to malignant cancer cells.

In effect, the Mayo Clinic virus makeover uses proteins secreted by cancer cells as the unique key to the virus' ignition. Their report on the topic appears in the Aug. 1 edition of Cancer Research (http://cancerres.aacrjournals.org).

The investigation was performed in laboratory mice that were transplanted with a human cancer. The process is still experimental -- and thus, years away from clinical use in humans. However, the Mayo results may be immediately useful in designing improved cancer treatments for humans. "Our work shows that oncolytic measles virus particle activation can be made dependent on substances secreted by cancer cells, and this enhances safety," explains Roberto Cattaneo, Ph.D., lead researcher on the Mayo team. "By doing this, our study broadens the safeguarding strategies possible to tightly restrict the targeted virus to cancer cells."

Significance of the Mayo Clinic Research
The Mayo researchers say their contribution is a key advance because it provides a method of designing a therapeutic virus that is safe, stable and that reliably targets and kills cancer cells. Importantly, it appears to greatly reduce the possibility that the virus would erroneously turn on and harm the patient by causing unintended infection.

As such, the Mayo innovation of the cancer-activated virus is a helpful safety advance for the promising experimental field of "oncolytic virotherapy." The phrase refers to t
'"/>

Contact: Bob Nellis
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
1-Aug-2006


Page: 1 2

Related biology news :

1. 2007-2008 Genzyme/ACMGF Clinical Genetics Fellowship In Biochemical Genetics award winner announced
2. Scientists honored with Excellence in Clinical Research Award
3. Clinical trial data regarding NKTR-061 will be presented at ATS International Conference
4. NIH awards VBI, Mayo Clinic $2.4M to study chronic rhinosinusitis
5. Clinical trial for diabetic macular edema
6. The Parkinsons Institute to conduct Phase III Clinical Trial of creatine for Parkinsons disease
7. Research and program highlights of the 2007 Annual Clinical Genetics Meeting, March 21-25, 2007
8. Arizona State University and Mayo Clinic join forces to develop cancer vaccine
9. Marshfield Clinics electronic health record first to receive CCHIT certification
10. American College of Medical Genetics -- 2007 Annual Clinical Genetics Meeting Announcement
11. October MCP: A special issue on Clinical Proteomics

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/17/2016)... Calif. , Nov. 17, 2016  AIC announces that it has just released ... in organizations that require high-performance scale-out plus high speed data transfer storage solutions. ... ... ... Setting up a high ...
(Date:11/14/2016)... -- xG Technology, Inc. ("xG" or the "Company") (Nasdaq: XGTI, ... use in challenging operating environments, announced its results for ... hold a conference call to discuss these results on ... below). Key Recent Accomplishments ... to acquire Vislink Communication Systems. The purchase is expected ...
(Date:6/22/2016)... , June 22, 2016   ... management and verification solutions, has partnered with ... software solutions for Visitor Management, Self-Service Kiosks ... provides products that add functional enhancements to ... provides corporations and venues with an automated ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... 2016 According to the ... Products (Consumable, Instruments, Automated Cell Expansion System), Cells ... Cell Research, Cancer, and Cell-Based Research), End-users (Biopharmaceutical ... Global Revenue, Trends, Growth, Share, Size and Forecast ... global cell expansion market is expected to reach ...
(Date:12/5/2016)... MDx announced today that it brought its NxGen Informed Prenatal Test in-house. ... improve customer service through shortened turnaround times and at the same time ... NxGen MDx. ... A decrease in turnaround times by 25% combined with ... the Grand Rapid headquarters. The NxGen Informed Prenatal Test uses ...
(Date:12/5/2016)... 2016 The U.S. Biotechnology industry ... billion of revenue and some $890 billion of total ... global biopharmaceuticals, and this figure is expected to exceed ... up these four equities for assessment: Northwest Biotherapeutics Inc. ... ACAD ), Acorda Therapeutics Inc. (NASDAQ: ...
(Date:12/4/2016)...  In five studies being presented today during the ... Exposition in San Diego , researchers ... delivery of life-saving treatments to patients with a variety ... carry therapies directly to the sites in the body ... substantial advantage over traditional, systemic methods. The studies highlight ...
Breaking Biology Technology:
Cached News: